Solara Active Pharma Sciences Limited — Updates, 24-01-2025: Press Release

**Financial Highlights:** Solara Active Pharma Sciences reported revenues of INR 3,018 Mn for Q3 FY25, reflecting a 21% increase year-over-year but a 13% decline quarter-over-quarter. Gross margins improved significantly to 55.4%, up 490 bps QoQ, reaching historical levels, while EBITDA margins were 19.6%, marking an increase of 180 bps QoQ. For FY25, the company maintains its EBITDA guidance of INR 2,300 to INR 2,600 Mn.

**Strategic Initiatives and Growth Drivers:** The company announced plans to carve out its CRAMS and Polymer business, along with the Vizag facility, into an independent entity. This move aims to streamline operations and focus on distinct value drivers, with estimated revenues from the new company projected at INR 1,200 Mn for FY25.

**Business Developments:** Solara's regulated markets contributed 76% to total revenues, showing a consistent growth trajectory. The company is focusing on enhancing profitability by optimizing operations and reducing debt.

**Market Position and Competitive Advantage:** With a significant market share and improved gross margins, Solara is well-positioned against competition. The proposed demerger is expected to strengthen its balance sheet while unlocking shareholder value.

**Investor Implications:** The focus on margin expansion, cost control, and a proactive restructuring strategy suggests a positive outlook for Solara’s growth and profitability, making it a potential area for investment for those looking for robust companies in the pharmaceutical sector.